Emerging synthetic biology toolkits to control gene expression and provide therapeutic avenues in cardiovascular disease.

Abstract

INTRODUCTION: Synthetic biology is an emerging field that integrates engineering principles, molecular innovations, interdisciplinary methodologies, and designer toolkits to create versatile and adaptable platforms for control, enhance, and reprogram signaling, phenotype, or function in biological systems and living organisms. Advances in mammalian synthetic biology have generated growing interest in its translational applications, including cardiovascular drug discovery and disease management. AREAS COVERED: This concise report highlights promising synthetic biology-inspired technologies that have been applied or can potentially apply to transgene regulation and disease management in cardiovascular medicine, such as tunable regulatory switches, programmable gene circuits, synthetic sensing modules, and gut-heart axis engineering. We also summarize recent translational progress in the field and discuss remaining obstacles, potential solutions, and future opportunities, with particular emphasis on the progression from laboratory concepts to practical applications in cardiovascular disease. EXPERT OPINION: Synthetic biology is steadily advancing toward translation. However, barriers for clinical implementation remain, including non‑mammalian components, immunogenicity, regulatory uncertainty, and broader ethical and safety concerns. Emerging solutions, including humanized molecular components, advanced monitoring strategies, and machine learning, may help mitigate those risks and expand the cardiovascular utility of synthetic biology. Stronger evidence and deeper clinical integration will position the field for future cardiovascular medicine.

Abstract as supplied by the indexing source. © the authors / publisher.